Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
MWN-AI** Summary
Scinai Immunotherapeutics Ltd. has announced expanded support from the Israel Innovation Authority (IIA) for its robotic aseptic fill and finish platform, enabling the company to access a full grant budget of NIS 5 million over two years. This funding is approximately 66% non-dilutive and will facilitate the acquisition and validation of a fully automated robotic-arm system designed to meet EU GMP Annex 1 standards. Scinai aims to validate the technology by the third quarter of 2026.
This initiative aligns with Scinai’s strategy to modernize its contract development and manufacturing organization (CDMO) capabilities, which has been propelled by the recent acquisition of Recipharm Israel Ltd. The partnership allows for a seamless transition from early clinical development to commercial manufacturing, enhancing the company’s operational capacity across its two Israeli sites — a biologics facility in Jerusalem and a small-molecule API site in Yavne.
CEO Amir Reichman emphasized that the expanded IIA support would enable focused investments in advanced manufacturing while maintaining financial discipline. This initiative is expected to improve Scinai's clinical manufacturing capabilities, reduce human intervention in sterile processes, and enhance batch consistency—all critical factors for contamination control in biotech production.
Scinai's COO, Elad Mark, further highlighted the importance of the robotic platform in advancing the company’s manufacturing capabilities to support complex biological programs. Additionally, Scinai is actively monitoring potential future IIA programs for industrial CAPEX investments, which could provide further opportunities for growth.
Overall, Scinai is positioning itself as a technology-driven CDMO partner for biotech firms, aiming to enhance its market offering through innovative manufacturing solutions and strategic collaborations.
MWN-AI** Analysis
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has recently announced the expanded support from the Israel Innovation Authority (IIA) for its robotic aseptic fill and finish platform, which is poised to enhance its capabilities in clinical manufacturing. With a funding commitment of NIS 5 million, approximately 66% of which is non-dilutive, Scinai is well-positioned to strengthen its existing contract development and manufacturing organization (CDMO) following its acquisition of Recipharm Israel Ltd.
Investors should view this development as a positive signal, as it reinforces Scinai's commitment to integrating advanced technologies into its manufacturing processes while minimizing the need for additional equity financing. The transition to robotic aseptic processing aligns with EU GMP Annex 1 standards, which could position Scinai favorably in a competitive market seeking higher compliance and quality standards in drug production.
The strategic collaboration with Recipharm not only diversifies Scinai's offerings but provides a smoother transition for clients navigating from early clinical stages to commercial production. This could enhance Scinai's attractiveness to emerging biotech firms looking for reliable manufacturing partners.
However, while the prospects appear bright, potential investors should remain cautious. The company's reliance on obtaining future non-dilutive funding, its ability to effectively integrate operations from Recipharm, and the successful validation of the new robotic platform are key risks that could impact its operational trajectory. Additionally, the company operates in a highly regulated industry, where compliance challenges can lead to unforeseen delays.
Overall, with a well-defined strategy and significant non-dilutive funding support, Scinai Immunotherapeutics offers a compelling investment opportunity. Investors are advised to monitor upcoming validation timelines and market developments, as these will be crucial in determining the company's future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
PR Newswire
JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support.
With this update, Scinai is now utilizing the full approved grant budget for the program, totaling NIS 5 million over two years, approximately 66% of which is non-dilutive funding.
The program supports the acquisition and validation of a fully automated, versatile robotic-arm aseptic fill & finish system designed to align with EU GMP Annex 1 standards. Validation of the system is targeted for completion in the third quarter of 2026.
The investment forms part of Scinai's broader strategy to expand and modernize its CDMO capabilities following the recent acquisition of Recipharm Israel Ltd. and the signing of a strategic commercial collaboration agreement with Recipharm. Together, the Jerusalem biologics facility and the newly acquired Yavne small-molecule site establish an integrated two-site development and manufacturing platform, while the Recipharm collaboration provides a defined pathway for clients to graduate from early clinical development to late-stage and commercial manufacturing within Recipharm's global network.
Robotic aseptic processing significantly reduces human intervention in sterile manufacturing, enhances reproducibility, and strengthens contamination control. The system is expected to expand Scinai's clinical manufacturing capabilities at its Jerusalem site and further reinforce its positioning as a technology-driven CDMO partner for emerging biotech companies.
"The expanded support from the Israel Innovation Authority strengthens our ability to invest in next-generation sterile manufacturing capabilities while maintaining disciplined capital allocation," said Amir Reichman, Chief Executive Officer of Scinai. "Following the Recipharm Israel acquisition and the launch of our commercial collaboration framework, we are focused on scaling our two-site CDMO platform and enhancing the technological depth of our biologics offering. Maximizing non-dilutive funding remains a core component of that strategy."
Elad Mark, Chief Operating Officer of Scinai, added: "The robotic aseptic fill and finish platform represents a significant step forward in our sterile manufacturing capabilities. Automated aseptic processing reduces operator intervention, enhances batch consistency, and strengthens contamination control in alignment with EU GMP Annex 1 requirements. This investment enhances our ability to support complex biologics programs and aligns with the broader expansion of our development and manufacturing footprint."
The Company is monitoring the anticipated launch of a potential new IIA program intended to support industrial CAPEX investments, which would be subject to approval of Israel's 2026 state budget and formal announcement by the Authority. Subject to the availability of such non-dilutive support, Scinai would evaluate opportunities to further enhance capabilities at its Yavne small-molecule site in alignment with its CDMO expansion strategy.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D pipeline.
The Company's wholly owned CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies. It operates two sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne.
The CDMO supports external clients from preclinical development through Phase I/II clinical supply, including biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization, analytical methods development and GMP production.
Through a strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm's global network. This structure enables continuity of development, streamlined tech transfer, and reduced scale-up risk as programs advance.
The CDMO unit engages with early-stage and emerging biotech companies and mid-size pharmaceutical companies outsourcing early development programs.
In parallel, Scinai is advancing, through its R&D unit, a focused immunology pipeline, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The Company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation.
Company website: www.scinai.com
Company Contacts
Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include statements regarding, among other things, the expected benefits of the Share Purchase Agreement and Commercial Collaboration Agreement with Recipharm, the anticipated expansion and scaling of the Company's CDMO platform, the expected validation and timing of the robotic aseptic fill and finish system, the anticipated benefits of robotic aseptic processing, potential future participation in Israel Innovation Authority programs, and the Company's strategic and capital allocation plans. Words such as "expects," "intends," "plans," "believes," "may," "will," "anticipates," "estimates," "targets," and similar expressions are intended to identify forward-looking statements.
These statements are based on current expectations and assumptions and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, without limitation: the risk that the expected benefits of the Share Purchase Agreement and Commercial Collaboration Agreement will not be realized; the risk that the Company will not successfully integrate or expand its CDMO operations; delays or challenges in the validation or commercialization of the robotic aseptic fill and finish system and its resulting effect on Scinai's clinical manufacturing capabilities; failure to obtain, or delays in obtaining, grants or other non-dilutive funding, including under the EU STEP program or potential Israel Innovation Authority programs; lower than anticipated revenues from the CDMO business; failure to secure new client agreements; risks relating to the Company's ability to maintain compliance with Nasdaq continued listing requirements; risks associated with the Company's need for additional capital; risks related to research and development activities, including delays in or unsuccessful results from preclinical or clinical studies; regulatory risks; and general market and economic conditions.
More detailed information regarding these and other risks and uncertainties is included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on May 7, 2025, and in the Company's subsequent filings with the SEC.
Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
SOURCE Scinai Immunotherapeutics Ltd.
FAQ**
How will the expanded support from the Israel Innovation Authority enhance Scanner Technologies Corp SCNI's robotic aseptic fill & finish platform and its overall CDMO capabilities?
What specific advancements in technology does Scanner Technologies Corp SCNI anticipate from the implementation of the robotic aseptic fill & finish system in terms of manufacturing efficiency and contamination control?
Can Scanner Technologies Corp SCNI provide more details on the strategic collaboration with Recipharm and its role in scaling the CDMO platform after the recent acquisition?
What are the projected timelines and key milestones for the validation of the robotic aseptic fill & finish platform at Scanner Technologies Corp SCNI, and how will these align with the company’s broader operational strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Scanner Technologies Corp (NASDAQ: SCNI).
NASDAQ: SCNI
SCNI Trading
-0.39% G/L:
$0.7749 Last:
13,224 Volume:
$0.75 Open:
